Immuno-Oncology | Specialty

Biomarkers and Novel Approaches in CRC

February 17th 2018

Reverce Study: Outcomes and Impact

February 17th 2018

Sequencing of Therapy in Refractory mCRC

February 17th 2018

Management of Side Effects With TAS-102

February 17th 2018

Proactive Side Effect Management With Regorafenib

February 17th 2018

Clinical Implications of the ReDOS Findings

February 17th 2018

The Regorafenib Dose Optimization Study

February 17th 2018

Treatment Options in Refractory mCRC

February 17th 2018

Treatment Goals in Refractory mCRC

February 17th 2018

Pembrolizumab Plus SBRT Active in Advanced Solid Tumors

February 17th 2018

The addition of pembrolizumab to stereotactic body radiotherapy induced an objective response rate of 13.2% among patients with advanced solid tumors.

Immunotherapy Poised to Move Forward Into Stage III NSCLC

February 16th 2018

A panel of several of the world’s foremost experts on immunotherapy in lung cancer discuss durvalumab and other emerging approaches for stage III NSCLC.

Dr. Sampath on Safety of Immunotherapy Plus Radiation in Lung Cancer

February 15th 2018

Sagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses the safety profile of immunotherapy in combination with radiation in the treatment of patients with lung cancer.

Pembrolizumab Update Solidifies Survival Benefit in Bladder Cancer

February 15th 2018

Joaquim Bellmunt, MD, PhD, discusses the updated pembrolizumab findings, as well as the future of immunotherapy in bladder cancer.

Other Promising Targets in TNBC

February 15th 2018

Role of the Androgen Receptor in TNBC

February 15th 2018

Combination Therapy for TNBC: Checkpoint Inhibitor + Chemotherapy

February 15th 2018

Checkpoint Inhibitor Monotherapy for TNBC

February 15th 2018

Antibody-Drug Conjugates in Treating TNBC

February 15th 2018

Paclitaxel vs Nab-Paclitaxel in Metastatic TNBC

February 15th 2018

No pCR in Patients After Neoadjuvant Chemotherapy in TNBC

February 15th 2018